BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 31123922)

  • 1. Treatment Strategies in ANCA-Associated Vasculitis.
    Emejuaiwe N
    Curr Rheumatol Rep; 2019 May; 21(7):33. PubMed ID: 31123922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of ANCA-associated vasculitis: new therapies and a look at old entities.
    Zand L; Specks U; Sethi S; Fervenza FC
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):182-93. PubMed ID: 24602467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Randomized, Controlled Trial.
    Tuin J; Stassen PM; Bogdan DI; Broekroelofs J; van Paassen P; Cohen Tervaert JW; Sanders JS; Stegeman CA
    Clin J Am Soc Nephrol; 2019 Jul; 14(7):1021-1028. PubMed ID: 31253599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of ANCA associated vasculitis.
    Wallace ZS; Miloslavsky EM
    BMJ; 2020 Mar; 368():m421. PubMed ID: 32188597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody: associated vasculitis-a meta-analysis.
    Kuzuya K; Morita T; Kumanogoh A
    RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ANCA-Associated Vasculitis: Core Curriculum 2020.
    Geetha D; Jefferson JA
    Am J Kidney Dis; 2020 Jan; 75(1):124-137. PubMed ID: 31358311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.
    Jones RB; Hiemstra TF; Ballarin J; Blockmans DE; Brogan P; Bruchfeld A; Cid MC; Dahlsveen K; de Zoysa J; Espigol-Frigolé G; Lanyon P; Peh CA; Tesar V; Vaglio A; Walsh M; Walsh D; Walters G; Harper L; Jayne D;
    Ann Rheum Dis; 2019 Mar; 78(3):399-405. PubMed ID: 30612116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
    Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
    Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease.
    Casal Moura M; Irazabal MV; Eirin A; Zand L; Sethi S; Borah BJ; Winters JL; Moriarty JP; Cartin-Ceba R; Berti A; Baqir M; Thompson GE; Makol A; Warrington KJ; Thao V; Specks U; Fervenza FC
    J Am Soc Nephrol; 2020 Nov; 31(11):2688-2704. PubMed ID: 32826324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New therapeutic strategies in lung vasculitis.
    Nasser M; Cottin V
    Curr Opin Pulm Med; 2020 Sep; 26(5):496-506. PubMed ID: 32740376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Cartin-Ceba R; Indrakanti D; Specks U; Stone JH; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Spiera RF; Monach PA; St Clair EW; Seo P; Tchao NK; Ytterberg SR; Brunetta PG; Song H; Birmingham D; Rovin BH;
    Arthritis Rheumatol; 2017 Jan; 69(1):169-175. PubMed ID: 27482943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seven clinical conundrums in the treatment of ANCA-associated vasculitis.
    Alba MA; Flores-Suárez LF
    Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S74-83. PubMed ID: 23663685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?
    Tesar V; Hruskova Z
    Expert Opin Pharmacother; 2015; 16(11):1683-702. PubMed ID: 26149512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in ANCA-Associated Vasculitis.
    Hassan RI; Gaffo AL
    Curr Rheumatol Rep; 2017 Feb; 19(2):6. PubMed ID: 28155022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab for treatment of severe renal disease in ANCA associated vasculitis.
    Geetha D; Hruskova Z; Segelmark M; Hogan J; Morgan MD; Cavero T; Eriksson P; Seo P; Manno RL; Dale J; Harper L; Tesar V; Jayne DR
    J Nephrol; 2016 Apr; 29(2):195-201. PubMed ID: 25986390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Outcomes in Children With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Morishita KA; Moorthy LN; Lubieniecka JM; Twilt M; Yeung RSM; Toth MB; Shenoi S; Ristic G; Nielsen SM; Luqmani RA; Li SC; Lee T; Lawson EF; Kostik MM; Klein-Gitelman M; Huber AM; Hersh AO; Foell D; Elder ME; Eberhard BA; Dancey P; Charuvanij S; Benseler SM; Cabral DA;
    Arthritis Rheumatol; 2017 Jul; 69(7):1470-1479. PubMed ID: 28371513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
    Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
    Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2017 Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis.
    Harigai M; Nagasaka K; Amano K; Bando M; Dobashi H; Kawakami T; Kishibe K; Murakawa Y; Usui J; Wada T; Tanaka E; Nango E; Nakayama T; Tsutsumino M; Yamagata K; Homma S; Arimua Y
    Mod Rheumatol; 2019 Jan; 29(1):20-30. PubMed ID: 30001655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
    Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
    Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in remission induction therapy for ANCA-associated vasculitis.
    Morris A; Geetha D
    Best Pract Res Clin Rheumatol; 2023 Mar; 37(1):101828. PubMed ID: 37244804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.